| Drug Name |
Tolcapone |
| Drug ID |
BADD_D02241 |
| Description |
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. |
| Indications and Usage |
Used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies. |
| Marketing Status |
approved; withdrawn |
| ATC Code |
N04BX01 |
| DrugBank ID |
DB00323
|
| KEGG ID |
D00786
|
| MeSH ID |
D000077867
|
| PubChem ID |
4659569
|
| TTD Drug ID |
D0Y7PG
|
| NDC Product Code |
50742-193; 0187-0938; 68682-938; 17511-119; 65085-0032; 76438-001 |
| UNII |
CIF6334OLY
|
| Synonyms |
Tolcapone | 3,4-Dihydroxy-5'-methyl-5-nitrobenzophenone | 3,4 Dihydroxy 5' methyl 5 nitrobenzophenone | SOM0226 | Ro 40-7592 | Ro 40 7592 | Ro 407592 | Ro-40-7592 | Ro407592 | Tasmar |
